RCTs: The Payer’s Mandate for AI Reimbursement

Digital health is flooded with AI solutions, and a lot of them even have FDA 510(k) clearances. But there’s a huge gap between getting regulatory approval and getting paid, and it’s a massive hurdle for even the best vertical AI healthcare companies. For any healthcare VC or digital health founder, this distinction isn’t academic, it’s everything, especially now that major insurance payers are demanding hard evidence from randomized controlled trials (RCTs) before they’ll authorize coverage.

Beyond Regulatory Clearance: The Payer’s Demand for RCTs

That FDA 510(k) you’re so proud of? It’s a critical first step, sure. It shows your Software as a Medical Device (SaMD) is “substantially equivalent” to another device already on the market. But that regulatory milestone, which confirms safety and efficacy in a controlled setting, will not make payers open their wallets. Payers are driven to manage costs and get value for their money, so they set a much higher bar for evidence: they want to see proof of better patient outcomes, lower healthcare utilization, or both, and that proof needs to come from rigorous, prospective clinical trials. This is why a long-term trial pipeline isn’t a ‘nice-to-have’, it’s your ticket to commercial survival. Just look at iRhythm Technologies and its Zio patch. Their early observational studies were useful, but the landmark mSToPS trial is what completely changed the reimbursement game. This was a massive randomized controlled trial, published in JAMA, that directly compared immediate rhythm monitoring with the Zio XT patch to the usual care for asymptomatic people with risk factors for atrial fibrillation mSToPS trial results in JAMA. With about 1,700 patients in the active monitoring arm, the trial delivered undeniable proof that proactive, continuous monitoring with the Zio patch led to earlier AFib diagnoses. That, in turn, allowed for quicker intervention and likely prevented strokes and other bad cardiovascular events. This kind of outcomes data, generated through a real RCT, was the key to securing national payer coverage and cementing iRhythm’s spot as a leader in cardiac monitoring. Their data moat, built on millions of labeled ECGs, plus this gold-standard evidence, created a wall that’s been nearly impossible for competitors to climb.

The Vertical Advantage: Deep Specialization and RCT Investment

The iRhythm story points to a clear pattern for investors. Vertical AI healthcare companies, the ones that go deep on a specific disease like cardiology, diabetes, behavioral health, or oncology, are just built better to run the focused, outcomes-driven RCTs that payers want to see. A horizontal platform trying to be a Swiss Army knife for every condition just can’t focus its resources. A disease-specific AI platform, on the other hand, can pour its money, clinical experts, and data collection into proving a tangible benefit for a specific group of patients. This focus allows for a few things:

• Targeted Trial Design: They can design RCTs to hit the exact clinical endpoints that matter for that one disease which makes it much more likely they’ll show a real impact.
• Deep Clinical Integration: These specialists usually get their AI tools deep inside existing clinical workflows (a huge advantage), which makes enrolling patients and grabbing data for trials a lot easier.
• Payer-Centric Value Propositions: Because they live and breathe a single disease pathway, these companies can walk into a meeting with a payer and spell out the value in terms they understand, fewer hospital stays, better medication adherence, or stopping a disease before it gets worse. For example, in cardiac prevention, Cleerly is all-in on this strategy. The company uses AI to analyze coronary plaque and has multiple randomized clinical trials running right now, which you can see on ClinicalTrials.gov Cleerly’s clinical trial pipeline. Their method of analyzing coronary CT angiography (CCTA) images to quantify plaque is a big change from the old way of just looking for stenosis. By putting its money into RCTs, Cleerly is trying to prove that its AI-driven analysis leads to more accurate risk stratification and personalized treatment, and in the end better patient outcomes, which is the only way to justify broad adoption and reimbursement. That kind of commitment to clinical validation is what separates them from the pack relying on weak retrospective studies or just an FDA letter.
  

  Why Investors Must Demand RCT Evidence

  For VCs and founders in healthcare, the lesson is simple: FDA clearance de-risks your regulatory path, not your commercial one. Putting your money into companies that actually execute big, serious randomized controlled trials isn’t just good clinical practice. It’s the core of a sustainable business in digital health. Observational pilots and retrospective analyses can be fine for generating a hypothesis or showing your tech works, but they almost never convince a major insurance payer to write a check. The biases and confounding factors in those kinds of studies leave too many open questions about whether your product actually caused the good outcome. If a company’s whole story is real-world evidence (RWE) with no clear plan for a prospective RCT, it’s going to have a very hard time getting broad market access and favorable reimbursement. Think about it. Clinical guidelines from groups like the American Heart Association and American College of Cardiology are built on high-tier evidence, and that means RCTs. If your trial data gets your product into those guidelines, you’ve got a powerful endorsement that resonates with both the doctors who prescribe and the payers who pay. Any startup that hasn’t built to GMLP (Good Machine Learning Practice) principles, doesn’t have a real QMS (Quality Management System) like ISO 13485 in place, and, most importantly, has no plan for a substantial RCT pipeline, is carrying a mountain of regulatory and commercial debt that’s going to blow up during due diligence.

  The Future of AI Health Adoption: A Methodology Rooted in Rigor

  If we want to see AI get widely adopted in clinics, it has to be built on a foundation of scientific rigor. We have to stop talking about AI in healthcare like it’s a tech demo and start talking about its real, measurable impact on patients. For investors, this means you have to look past the shiny algorithm and dig into the clinical validation roadmap. Do they have a real plan for getting a Category I CPT code? What’s their Predetermined Change Control Plan (PCCP) for when the algorithm inevitably drifts, and are they committed to validating their evolving models with real-world data and new trials? The road to commercial success for a vertical AI healthcare company isn’t paved with cool algorithms and an FDA clearance letter. It’s paved with the gold standard of clinical evidence: the randomized controlled trial. The companies that get this will be the ones that actually succeed in changing healthcare.